Loading clinical trials...

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine | Clinical Trials | Clareo Health

COMPLETEDPHASE2/PHASE3

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

REcovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM)

NCT05513560•University Health Network, Toronto

Summary

The researchers propose to develop a Canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions. Because this is an adaptive trial, arms can be dropped if found to be ineffective and new arms can be added. Interventions will last for 2 months and participants will be followed for an additional 4 months (6 months total). Approximately 800-1000 patients with Long COVID will be recruited across Canada. Results from this trial will accelerate the availability of high-quality, real-time evidence and solutions to enable Canada to improve the clinical care of patients with Long COVID.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age ≥18 years;
•2. Positive COVID-19 test by nasopharyngeal swab RT-PCR (reverse transcription polymerase chain reaction) test, antibody or antigen tests at least 3 months prior to randomization; OR Presumed COVID-19 assessed by the site investigator (no positive COVID-19 test) with acute illness after October 15, 2019.
•3. Patients should be treated with standard of care therapies (as discussed in the study manual) for at least 4 weeks prior to entry into trial.
•4. Lingering COVID-19 symptoms beyond 3 months from onset of acute COVID and symptoms have lasted at least 2 months. The onset of COVID is considered the earliest of two dates: the date of positive test or the date of first symptoms;
•5. Lingering symptoms from COVID-19 present at the time of randomization.
•6. Female patients of childbearing potential (as assessed by the overseeing Investigator) who are sexually active must agree to practice true abstinence or use effective methods of contraception while on study treatment. Effective methods of contraception must be discussed and approved by the overseeing Investigator.
•7. Must be able to provide informed consent and both willing and able to comply with study requirements.

Exclusion Criteria

•1. Patients who had mechanical ventilation or extracorporeal membrane oxygen (ECMO) for COVID-19;
•2. Current end-organ failure, organ transplantation, or current hospitalization in acute care hospital;
•3. Contraindications to all of the study interventions;
•4. Co-enrolment in another interventional trial (co-enrolment in an observational study is permitted);
•5. Currently pregnant or breastfeeding.

Locations (3)

The Ottawa Hospital

Ottawa, Ontario, Canada

University Health Network, Osteoporosis Department

Toronto, Ontario, Canada

Mount Sinai Hospital

Toronto, Ontario, Canada

Key Dates

Start Date

May 31, 2023

Primary Completion Date

March 31, 2025

Completion Date

December 31, 2025

Last Updated

February 23, 2026

Enrollment

460

ACTUAL participants

Conditions

Long COVIDPost COVID ConditionPost Acute Sequelae of COVID-19

Interventions

Ibudilast

DRUG

Pentoxifylline

DRUG

Placebo

OTHER

Taurine Supplementation in Long COVID

NCT06721949

Long COVID

View study

RECRUITINGPHASE3

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287

Long COVIDSars-CoV-2 Infection+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine

Inclusion Criteria

Exclusion Criteria

Taurine Supplementation in Long COVID

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Presynaptic Imaging in Major Depressive Episodes After COVID-19

Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome

Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

A Study to Examine Anktiva for the Treatment of COVID-19.